03 March 2023 : Original article
Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience
Maha M. Islami
1CDE*, Mansoor Ahmed Khan 23ABCDEF, Mohammed A. Aseeri 23A, Majed A. Alshamrani 23E, Abdelmajid Alnatsheh 23ACDE, Sameer Alamoudi 34ADE, Ahmed A. Alzahrani 5E
DOI: 10.12659/AOT.938585
Ann Transplant 2023; 28:e938585
Table 1 Patient characteristics.
| Overall | Zarzio® | Neupogen® | ||
|---|---|---|---|---|
| Autologous | Number of patients | 97 | 49 (51%) | 48 (49%) |
| Male | 59 (61%) | 28 | 31 | |
| Female | 38 (39%) | 21 | 17 | |
| Age | 37 (16–65) | 37 (16–65) | 39 (21–63) | |
| Diagnosis | ||||
| MM | 29 | 15 | 14 | |
| HL | 45 | 24 | 21 | |
| DLBCL | 11 | 7 | 4 | |
| Other | 12 | 4 | 8 | |
| Chemotherapy + filgrastim | 74 | 35 | 39 | |
| Monotherapy | 623 | 14 | 9 | |
| Allogenic | Number of patients | 17 | Allogenic Stem cell transplant patients did not receive any G-CSF as G-CSF was received by healthy donors for mobilization of stem cells and their details are mentioned below in front of healthy donors | |
| Male | 6 (35%) | |||
| Female | 11 (65%) | |||
| Age | 37 (16–59) | |||
| Diagnosis | ||||
| ALL | 4 | 1 | 3 | |
| AML | 10 | 6 | 4 | |
| Other | 3 | 1 | 2 | |
| Healthy donors | Number of donors | 17 | 8 | 9 |
| Male | 10 (59%) | 2 | 8 | |
| Female | 7 (41%) | 6 | 1 | |
| Age | 33 (9–52) | 38 (18–47) | 27 (9–52) | |